BD Biosciences and StemCell Technologies Sign License Agreements with WARF
Commercialization of Novel Culture Media and Surfaces for Human Embryonic Stem Cell Research
BD Biosciences, a segment of global medical technology company BD (Becton, Dickinson and Company), and StemCell Technologies, Inc. announced that they have each entered into a worldwide license agreement with the Wisconsin Alumni Research Foundation (WARF). The agreements will allow BD Biosciences and StemCell Technologies to develop and commercialize novel growth media and validated tissue culture surfaces that together offer a complete cell culture environment for human embryonic stem cells (hESC). Financial details of the agreement were not disclosed.
The agreements also mark the beginning of a strategic collaboration between BD Biosciences and StemCell Technologies, which aims to provide products that are superior in quality, performance and reliability to facilitate and support the field of stem cell research. The development of these products arises from primary research performed by Dr. James Thomson and Dr. Tenneille Ludwig at the University of Wisconsin - Madison and the WiCell(TM) Research Institute, a non-profit subsidiary of WARF.
The first commercial products expected from these new license agreements and collaboration are a defined medium and compatible tissue culture surface to support the feeder-independent maintenance of hESC - a major advance in current state-of-the-art cell culture conditions.
Topics
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Gellan_gum

Boys reach sexual maturity younger and younger - The phase between being physically but not socially adult is getting longer
Shire's Vyvanse Will Attain Blockbuster Status by 2017 in the Attention-Deficit/Hyperactivity Disorder Drug Market - Emerging Nonstimulant Drugs Will Earn Less Than 15 Percent Share of the ADHD Market in 2017, According to a New Report from Decision Resources
CellCept reaches positive results in Phase III trial in Lupus Nephritis
